Search research articles
Contact Us
Filters
Showing results (271-280 of 276) with videos related to
Page
of 28
Sort By:
You have reached the last page of results.
This site can display upto 276 results.
Cancer Chemotherapy and Pharmacology
|
February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Surgical Endoscopy
|
October 1, 2004
Laparoscopic resection of colon Cancer: consensus of the European Association of Endoscopic Surgery (EAES)
R Veldkamp, M Gholghesaei, H J Bonjer, et al.
Nature Medicine
|
June 5, 2025
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
Kelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
Physical Review Letters
|
February 1, 2008
Measurement of nuclear transparency for the A(e,e'pi+) reaction
B Clasie, X Qian, J Arrington, et al.
Page
of 28
Search research articles
Search
Showing results (271-280 of 276) with videos related to
Sort By:
Page
of 28
You have reached the last page of results.
This site can display upto 276 results.
Cancer Chemotherapy and Pharmacology
|
February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Surgical Endoscopy
|
October 1, 2004
Laparoscopic resection of colon Cancer: consensus of the European Association of Endoscopic Surgery (EAES)
R Veldkamp, M Gholghesaei, H J Bonjer, et al.
Nature Medicine
|
June 5, 2025
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
Kelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
Physical Review Letters
|
February 1, 2008
Measurement of nuclear transparency for the A(e,e'pi+) reaction
B Clasie, X Qian, J Arrington, et al.
Page
of 28